Skip to main content
Clinical Trials/NCT04161729
NCT04161729
Completed
Phase 4

Effects of Intraoperative Magnesium Sulfate on Pain Relief, Hemodynamics and Quality of Recovery After Spine Surgery

Aristotle University Of Thessaloniki1 site in 1 country74 target enrollmentJanuary 28, 2020

Overview

Phase
Phase 4
Intervention
Magnesium Sulfate
Conditions
Analgesia
Sponsor
Aristotle University Of Thessaloniki
Enrollment
74
Locations
1
Primary Endpoint
Analgesics consumption postoperatively in morphine equivalents
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The treatment of postoperative pain is increasingly based on a multimodal approach and although opioids remain the drug of choice, they are often used in combination with other analgesics (paracetamol, cyclooxygenase inhibitors or non-steroidal anti-inflammatory drugs) and co-analgesic agents (clonidine and anti- NMDA such as ketamine or MgSO4). The rationale for combined analgesia is to achieve additive or synergistic analgesic properties while decreasing the incidence of side effects by reducing the dose of each agent. Nociceptive stimuli are known to activate the release of the excitatory amino acid glutamate in the dorsal horn of the spinal cord. The resultant activation of NMDA receptors causes calcium entry into the cell and triggers central sensitisation. This mechanism is involved in the perception of pain and mainly accounts for its persistence during the postoperative period.

Although magnesium is not a primary analgesic in itself, it enhances the analgesic actions of more established analgesics as an adjuvant agent. Magnesium produces a voltage-dependent block of NMDA receptors and has been reported to have analgesic properties that might be related to this inhibiting property. Magnesium sulfate has been reported to be effective in perioperative pain treatment and in blunting somatic, autonomic and endocrine reflexes provoked by noxious stimuli.

When magnesium was used intraoperatively, many researchers reported that it reduced the requirement for anesthetics and/or muscle relaxants.

Intraoperative use of magnesium sulfate can also be associated with decreased incidences of nausea and vomiting after surgery, which could have been due to the lower consumption of anesthetics (i.e. volatile agents), rather than any antiemetic effect of magnesium sulfate. In addition, perioperative i.v. administration of magnesium sulfate has another advantageous effect, as it decreases the incidence of shivering by up to 70-90%. Previous studies investigating the analgesic efficacy of MgSO4 in general, gynaecological, ophthalmic and orthopaedic surgery have shown conflicting results, while reports regarding spine surgery are extremely limited.

Our study was designed to investigate the effects of MgSO4 on perioperative pain relief and postoperative quality of recovery after lumbar laminectomy surgery.

Detailed Description

Each participant will receive standard monitoring (ECG, SpO2, capnography, SBP, oesophageal temperature, accelerography) and an intravenous access will be established. The level of anaesthesia will be monitored with the bispectral index (BIS), targeting to a BIS level 40-50. Group M patients will receive intravenous magnesium sulfate 20 mg/kg over a 15-min period before induction of anaesthesia and 20 mg/kg/h by continuous i.v. infusion during the operation. Group C will be given isotonic solution of 0.9% in the same volume as the study drug. A standard anesthesia protocol will be applied involving propofol 2mg/kg (iv) and fendanyl 2 μg/kg (iv). Cis-atracurium 0.2 mg/kg (iv) will be given to facilitate endotracheal intubation. Anaesthesia will be maintained with air 50% and oxygen 50%, and desflurane adjusted to achieve a target BIS between 40 and 50. Remifentanil will be added to the anesthesia regimen as needed. Hemodynamic parameters will be recorded upon * Baseline: Before the administration of the tested drug * T5: 5 minutes after the administration of the tested drug * T10: 10 minutes after the administration of the tested drug * T15: 15 minutes after the administration of the tested drug * Ts: surgical incision * T30: 30 minutes after the administration of the tested drug * T45: 45 minutes after the administration of the tested drug * T60: 60 minutes after the administration of the tested drug * T90: 90 minutes after the administration of the tested drug * T120: 120 minutes after the administration of the tested drug * T180: 180 minutes after the administration of the tested drug Low arterial blood pressure during surgery defined as a mean blood pressure value \< 50 mmHg will be treated by a bolus of 5 mg ephedrine administered intravenously or phenylephirne civ for persistent hypotension. Also, time to accelerography recording indicating the appropriateness of neuromuscular block for intubation, mean expired desflurane concentration (from 30 min after skin incision to the end of surgery), boluses of ephedrine and total intraoperative remifentanil consumption will be recorded. Postoperative analgesic protocol will involve paracetamol 1 mg (iv), lornoxicam 8mg (iv) and morphine 3 mg (upon request). Postoperatively pain assessment will be performed by Visual Analogue Scale (VAS), Verbal Rating Scale (VRS) and Numerical Rating Scale (NRS) at emergence from anesthesia and 2, 4, 6, and 24 h in the study period. Time to first analgesic request and total analgesics consumption postoperatively (morphine equivalents) will be recorded. Episodes of shivering, as well as episodes of nausea and vomiting (PONV), will be recorded at emergence and thereafter, throughout the study period. Finally, patients' global satisfaction will be assessed the first day after surgery using a 5-grade scale (1= worst discomfort ever experienced in their life and 5= totally satisfied during the immediate postoperative period).

Registry
clinicaltrials.gov
Start Date
January 28, 2020
End Date
May 5, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Georgia Tsaousi

Assistant Professor

Aristotle University Of Thessaloniki

Eligibility Criteria

Inclusion Criteria

  • Adult patients aged between 18 and 80 years
  • ASA Physical status 1 to 3
  • Elective or semi-elective lumbar laminectomy surgery
  • Signed informed consent

Exclusion Criteria

  • Under medication with calcium channel blockers or magnesium
  • Drugs or alcohol abuse
  • Neurological disorders
  • Intracardiac block
  • Hepatic failure
  • Renal failure
  • Pregnancy

Arms & Interventions

Magnesium sulfate

Magnesium sulfate 20 mg/kg intravenous over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.

Intervention: Magnesium Sulfate

Magnesium sulfate

Magnesium sulfate 20 mg/kg intravenous over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.

Intervention: Isotonic saline 0.9%

Isotonic solution 0.9%

Isotonic solution 0.9% in the same volume as the study drug using identical pattern of administration.

Intervention: Magnesium Sulfate

Isotonic solution 0.9%

Isotonic solution 0.9% in the same volume as the study drug using identical pattern of administration.

Intervention: Isotonic saline 0.9%

Outcomes

Primary Outcomes

Analgesics consumption postoperatively in morphine equivalents

Time Frame: 24 hours after the emergence from anesthesia

The difference in analgesic consumption (assessed as mg of morphine equivalents) postoperatively after intravenous infusion of magnesium sulfate or isotonic saline 0.9%

Secondary Outcomes

  • Time to first analgesic request in minutes(24 hours after the emergence from anesthesia)
  • Analgesics consumption intraoperatively(180 minutes intraoperatively)
  • Pain intensity(10 minutes after emergence from anesthesia, 2, 4 and 6 hours after the emergence from anesthesia)

Study Sites (1)

Loading locations...

Similar Trials